Skip to main content

Advertisement

SpringerLink
Log in

Comparison of the qSOFA and CRB-65 for risk prediction in patients with community-acquired pneumonia

  • Letter
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kolditz M, Ewig S, Hoffken G (2013) Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 41:974–984

    Article  CAS  PubMed  Google Scholar 

  2. Singer M, Deutschman CS, Seymour CW et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801–810

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:762–774

    Article  CAS  PubMed  Google Scholar 

  4. Lim WS, van der Eerden MM, Laing R et al (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377–382

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wang JY, Chen YX, Guo SB, Mei X, Yang P (2016) Predictive performance of quick Sepsis-related Organ Failure Assessment for mortality and intensive care unit admission in patients with infection at the ED. Am J Emerg Med. doi:10.1016/j.ajem.2016.06.015

    Google Scholar 

  6. Chen YX, Wang JY, Guo SB (2016) Use of CRB-65 and quick Sepsis-related Organ Failure Assessment to predict site of care and mortality in pneumonia patients in the emergency department: a retrospective study. Crit Care 20:167

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

Grants: CAPNETZ was founded by a BMBF Grant (01KI07145) 2001-2011. CAPNETZ is a multidisciplinary approach to better understand and treat patients with community-acquired pneumonia. The network has only been made possible by the contribution of many investigators. We are especially indebted to the work of the investigators in the local clinical centers (LCC) who established and kept contact to all practitioners, physicians, and respiratory specialists cooperating within the network. Members of the CAPNETZ study group except the authors: M. Dreher, C. Cornelissen (Aachen); W. Knüppel (Bad Arolsen); D. Stolz (Basel); N. Suttorp, P. Creutz (Berlin, Charité); T. Bauer, T. Sabha (Berlin); W. Pankow, A. Lies, D. Thiemig (Berlin-Neukölln); B. Hauptmeier, S. Ewig, D. Wehde (Bochum); M. Prediger, S. Schmager (Cottbus); G. Höffken, M. Kolditz, B. Schulte-Hubbert, S. Langner (Dresden), T. Welte, G. Barten, M. Abrahamczik, J. Naim, W. Kröner, T. Illig, N. Klopp (Hannover); P. Ravn, A. Vestergaard-Jensen, G. Baunbaek-Knudsen (Hillerød); C. Kroegel, M. Pletz, J. Happe, J. Frosinski, J. Winning, A. Moeser (Jena); K. Dalhoff, K. Dageförde, K. Franzen, F. Hyzy, H. Schmieg, P. Parschke, P. Thiemann, J. Ahrens, T. Hardel (Lübeck); G. Rohde, J. Drijkoningen (Maastricht); H. Buschmann, R. Kröning (Paderborn); H. Schütte (Potsdam), T. Schaberg, I. Hering (Rotenburg/Wümme); C. Kropf-Sanchen (Ulm); T. Illmann, M. Wallner (Ulm); and all study nurses.

Author information

Authors and Affiliations

  1. Division of Pulmonology, Medical Department I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany

    Martin Kolditz

  2. Research Group Clinical Epidemiology, Integrated Research and Treatment Center, Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany

    André Scherag

  3. Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

    Gernot Rohde

  4. Thoraxzentrum Ruhrgebiet, Department of Respiratory and Infectious Diseases, EVK Herne and Augusta-Kranken-Anstalt Bochum, Bochum, Germany

    Santiago Ewig

  5. Department of Respiratory Medicine, Medizinische Hochschule Hannover, Hannover, Germany

    Tobias Welte

  6. Center for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany

    Mathias Pletz

  7. CAPNETZ STIFTUNG, Hannover, Germany

    Gernot Rohde, Tobias Welte & Mathias Pletz

  8. Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hannover, Germany

    Gernot Rohde & Tobias Welte

Authors
  1. Martin Kolditz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. André Scherag
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gernot Rohde
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Santiago Ewig
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tobias Welte
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mathias Pletz
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the CAPNETZ Study Group

Corresponding author

Correspondence to Martin Kolditz.

Ethics declarations

Conflicts of interest

Dr. Kolditz reports personal fees from Pfizer, Gilead, Novartis, Astra-Zeneca, Basilea, Böhringer-Ingelheim, Bayer, outside the submitted work. Dr. Scherag reports grants from Federal Ministry of Education and Research (BMBF), Germany, during the conduct of the study. Dr. Rohde reports personal fees from Pfizer, Novartis, Bayer, Astra Zeneca and Chiesi outside the submitted work. Dr. Welte reports grants from Ministry of Research and Education, during the conduct of the study; personal fees from AstraZeneca, Bayer, Basilea, Infectopharm, Pfizer, outside the submitted work. Dr. Ewig and Dr. Pletz have nothing to disclose.

Additional information

The members of the CAPNETZ study group (except the authors) are listed in the Acknowledgments.

Take-home message: In this first multicenter validation of the qSOFA in patients with CAP, accuracy for adverse outcome prediction of the qSOFA was similar to CRB. Sensitivity of the qSOFA was higher and specificity was lower as compared to CRB. Additionally, optimal low risk prediction is achieved by considering the criterion age in both scores.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 64 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kolditz, M., Scherag, A., Rohde, G. et al. Comparison of the qSOFA and CRB-65 for risk prediction in patients with community-acquired pneumonia. Intensive Care Med 42, 2108–2110 (2016). https://doi.org/10.1007/s00134-016-4517-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-016-4517-y

Keywords

Search

Navigation